You are here

BIOSTRATAGIES LC

Company Information
Address
504 UNIVERSITY LOOP E
JONESBORO, AR 72401
United States



Information

UEI: PE6MEQZRFW63

# of Employees: 1


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: Yes

Woman Owned: No



Award Charts




Award Listing

  1. Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)

    Amount: $1,500,000.00

    PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sa ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases

    Amount: $295,923.00

    Mucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, mus ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  3. Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS

    Amount: $390,497.00

    Krabbe disease (globoid cell leukodystrophy) is a rare inherited disorder caused by a deficiency in the lysosomal enzyme galactosylceramidase (GALC) leading to destruction of the protective coating (m ...

    SBIRPhase I2022Department of Health and Human Services National Institutes of Health
  4. Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery

    Amount: $250,000.00

    The current inability to effectively deliver corrective doses of lysosomal enzymes to key cells involved in muscular disease symptoms remains a significant hurdle for rare lysosomal disorders (LSD) su ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  5. Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization

    Amount: $2,049,999.00

    The long-range goal of this research is to develop an enzyme replacement therapy (ERT) technology for genetic metabolic diseases that is effective in mitigating the problem of immune sensitization tha ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  6. Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease

    Amount: $293,232.00

    The current inability to effectively deliver corrective doses of lysosomal enzymes to key cells involved in cardiovascular and cerebrovascular disease remains a significant hurdle for rare lysosomal d ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  7. MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme

    Amount: $225,000.00

    BioStrategies LC is developing the plant galactose binding lectinRTBas an enzyme carrier capable of expanding delivery of enzyme replacement therapiesERTstohardto treatorgans and tissues such as boneT ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  8. Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease

    Amount: $2,438,483.00

    The goal of this SBIR proposal is to develop an effective enzyme replacement therapyERTfor patients suffering from GMGangliosidosis by applying a novel ERT enzyme lectin fusion delivery strategy devel ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  9. Improving MPS I ERT Efficacy through Lectin Mediated Delivery

    Amount: $1,237,037.00

    The long term goal of this project is to develop an improved ERT for MPS I patients with innovations that enhance ERT delivery and disease correction in hard to treat organs such as the brain while in ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  10. Improving MPS I ERT Efficacy through Lectin-Mediated Delivery

    Amount: $2,384,044.00

    The long term goal of this project is to develop an improved ERT for MPS I patients with innovations that enhance ERT delivery and disease correction in hard to treat organs such as the brain while in ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government